Business Context and Reporting Period
Organogenesis Holdings Inc. (ORGO) filed a Form 8-K on November 27, 2024, reporting the entry into a material definitive agreement. The filing details a stock repurchase transaction with the GN 2016 Family Trust u/a/d August 12, 2016, a beneficial owner of Glenn H. Nussdorf, a member of the Company's Board of Directors.
Key Financial Metrics and Transaction Details
- Transaction Type: Stock Repurchase Agreement.
- Shares Repurchased: 500,000 shares of Class A Common Stock.
- Purchase Price: $4.057 per share.
- Total Consideration: Approximately $2.03 million (500,000 shares x $4.057).
- Pricing Basis: 10-day trailing volume weighted average price as of market close on November 26, 2024.
- Funding Source: Proceeds from the sale of Series A Convertible Preferred Stock to Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P. (announced November 12, 2024).
- Expected Closing Date: On or around December 3, 2024.
The filing does not provide updated revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes and Governance
The repurchase was approved by the Audit Committee and a Transaction Committee of the Board. This transaction represents a reduction in the Company's outstanding share count funded by recent capital raising activities. No other material changes to financial position or operations were disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of new risks or contingencies beyond the standard disclosure that the description of the agreement is qualified by reference to the full agreement attached as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the final closing date and settlement of the 500,000 share repurchase.
- Confirm the impact of this repurchase on the Company's total outstanding share count and cash balance.
- Review the terms of the Series A Convertible Preferred Stock sale to Avista Healthcare Partners to understand the full capital structure implications.
- Check for any subsequent filings regarding the GN 2016 Family Trust's remaining holdings post-repurchase.